Truist Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.
Stocks · News reference
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.
BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29
BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.
BKV shares are trading higher after the company announced that a subsidiary executed into an equipment supply contract.
BKV Announces Contract With Unnamed Supplier For About 1,200 MW Of Gas-Fired Power Equipment; Unnamed Hyperscaler, Intended Off-Taker, To Reimburse About 90% Of Payments Through March 31, 2027
8-K filing — BKV Corp (BKV)
Filed: 2026-10-07 AccNo: 0001104659-26-114193 Size: 217 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits